Anaplastic Large-cell Lymphoma in Children: State of the Art in 2023.

Anaplastic large-cell lymphoma is a rare disease and account for approximately 10% to 15% of pediatric non-Hodgkin lymphomas. They are characterized by extended stages, a high frequency of B signs and extra nodal involvement. Multiagent chemotherapy cures ∽60% to 75% of patients and relapse occurs in 35% of cases.

Epidemiological and clinical characteristics of children with peripheral neuroblastic tumors: a study on a Moroccan population.

Purpose: Peripheral neuroblastic tumors are the most common extracranial cancers found in children, and they are characterized by a diverse spectrum of clinical manifestations and heterogeneous behaviors. This study aimed to investigate the epidemiological and clinical characteristics of children with peripheral neuroblastic tumors admitted to the Department of Pediatric Hematology and Oncology of the Hospital August 20 in Casablanca.

Methods: The medical files of 48 children with peripheral neuroblastic tumors addressed to our department between February 2018 and February 2023 were reviewed.

Treatment and evaluation of recurrence for antrochoanal polyps by endoscopic large middle meatal antrostomy, clinical case series of 25 patients.

Introduction: The Endoscopic approach for complete removal of antrochoanal polyp is considered a safe and effective procedure with the best control of the attachments of antrochoanal polyps. The mains of our study are to review the clinical features and evaluate the recurrence in the patients affected by antrochoanal polyps (ACPs) and surgically treated by endoscopic middle meatal antrostomy.

Methods: The present research is a retrospective study.

Outcome of Acute Myeloid Leukemia in Children Adolescents and Young Adults Treated with an Uniform Protocol in Casablanca, Morocco.

Treatment of acute myeloblastic leukemia in children, adolescents and young adults (AYA) is a challenge in low-income countries. To evaluate treatment outcomes of children (≤ 15 years) and AYA (15-30 years) diagnosed with novo AML and treated in a single center according to the AML-MA 2011 protocol. From January 2011 to December 2015, eligible patients (age ≤ 30 years) with novo AML had been enrolled on a uniform treatment protocol.